Santen Pharmaceutical saw the highest growth of 99% in patent filings and 199% in grants in February in Q1 2024. Compared to Q4 2023, Q1 2024 saw an increase in patent filings by 49% and grants by 99%. GlobalData’s DataBook provides a comprehensive analysis of Santen Pharmaceutical‘s patent filings and grants. Buy the databook here.

Smarter leaders trust GlobalData

Santen Pharmaceutical has been focused on protecting inventions in United States(US) with five publications in Q1 2024

The United States(US) Patent Office dominates the patent filings and grants with nearly 50% filings and 20% grants. The United States(US), European Patent Office(EPO), South Korea(KR), and Canada(CA) patent Office are among the top ten patent offices where Santen Pharmaceutical is filings its patents. Among the top granted patent authorities, Santen Pharmaceutical has 20% of its grants in United States(US), 20% in European Patent Office(EPO) and 20% in South Korea(KR).

AbbVie and Regeneron Pharmaceuticals could be the strongest competitors for Santen Pharmaceutical

In terms of grant share, Santen Pharmaceutical stands in tenth position among its competitors. AbbVie and Regeneron Pharmaceuticals secured the top positions according to recent patent publication data.

Patents related to climate change and rare diseases lead Santen Pharmaceutical's portfolio

Santen Pharmaceutical has the highest number of patents in climate change followed by, rare diseases. For climate change, nearly 100% of patents were filed and 50% of patents were granted in Q1 2024.

Glaucoma related patents lead Santen Pharmaceutical portfolio followed by ocular hypertension, and hypertension

Santen Pharmaceutical has highest number of patents in glaucoma followed by ocular hypertension, hypertension, allergic conjunctivitis, and corneal neovascularization. For glaucoma, nearly 33% of patents were filed and 3% of patents were granted in Q1 2024.

For comprehensive analysis of Santen Pharmaceutical's filings and grants, buy the databook here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData patents database covers bibliographic from all 100+ patenting authorities. All patents are tagged to 18+ industries and 300+ sub-sectors based on technology classification, keywords, and associated companies. They are also tagged to various industries themes (100+) and technology domains (1800+) of focus.

Patents database further disambiguates assignee names (13m names) and associate corporate tree hierarchy in current/point in time ownerships (320k entities). GlobalData sources content directly from national patent offices on a weekly basis.